Damora Therapeutics, Inc.
DMRA
$24.16
$1.074.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 139.43% | -36.66% | -29.51% | -41.40% | -46.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 911.67% | -17.81% | -25.78% | -54.73% | -54.51% |
| Operating Income | -911.67% | 17.81% | 25.78% | 54.73% | 54.51% |
| Income Before Tax | -2,873.66% | 19.17% | 35.18% | 53.79% | -4.23% |
| Income Tax Expenses | 650.00% | -- | -90.48% | -- | -- |
| Earnings from Continuing Operations | -2,877.84% | 19.31% | 35.61% | 53.75% | -4.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,877.84% | 19.31% | 35.61% | 53.75% | -4.11% |
| EBIT | -911.67% | 17.81% | 25.78% | 54.73% | 54.51% |
| EBITDA | -913.32% | 17.81% | 25.83% | 54.78% | 54.42% |
| EPS Basic | -2,543.31% | 30.38% | 47.19% | 62.06% | 14.08% |
| Normalized Basic EPS | -925.34% | 30.26% | 34.95% | 62.09% | 69.84% |
| EPS Diluted | -2,543.31% | 30.38% | 47.19% | 62.06% | 14.08% |
| Normalized Diluted EPS | -925.34% | 30.26% | 34.95% | 62.09% | 69.84% |
| Average Basic Shares Outstanding | 12.66% | 15.90% | 21.94% | 21.90% | 21.16% |
| Average Diluted Shares Outstanding | 12.66% | 15.90% | 21.94% | 21.90% | 21.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |